Prelude Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference
January 04, 2022 07:00 ET
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive...
Prelude Therapeutics to Participate at the 4th Annual Evercore ISI HealthCONx Conference
November 23, 2021 07:00 ET
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive...
Prelude Therapeutics Announces Third Quarter 2021 Financial Results and Operations Update
November 12, 2021 08:00 ET
|
Prelude Therapeutics, Inc.
PRT543 and PRT811 Demonstrate Favorable Safety Profile, Tolerability and Evidence of Preliminary Clinical Activity in Phase 1 Dose Escalation in Unselected Patients Phase 1 Dose Expansion Ongoing...
Prelude Therapeutics Announces IND Clearance for PRT2527, a Highly Selective CDK9 Inhibitor
November 08, 2021 09:00 ET
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that the United States Food and Drug...
Prelude Therapeutics Announces Presentation of Encouraging Data from Multiple Programs at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
October 07, 2021 09:00 ET
|
Prelude Therapeutics, Inc.
– Lead oral PRMT5 inhibitors PRT543 and PRT811 demonstrate favorable safety profile, evidence of preliminary clinical activity including durable responses and high levels of target inhibition of PRMT5...
Prelude Therapeutics Announces Participation at Two Upcoming Virtual Investor Conferences
September 02, 2021 07:00 ET
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that members of its management team will...
Prelude Therapeutics Announces Second Quarter 2021 Financial Results and Operations Update
August 12, 2021 07:30 ET
|
Prelude Therapeutics, Inc.
- Data from Dose Escalation Portion of Phase 1 Trials of Lead Oral PRMT5 Inhibitors PRT543 and PRT811 to be Presented in 4Q21 – - Enrollment Ongoing in Multiple Expansion Cohorts in Phase 1 Trial of...
Prelude Therapeutics Announces Appointment of Martin Babler to its Board of Directors
July 19, 2021 07:00 ET
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., July 19, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the appointment of Martin Babler to its...
Prelude Therapeutics Announces First Quarter 2021 Financial Results and Operations Update
May 11, 2021 07:30 ET
|
Prelude Therapeutics, Inc.
- Enrollment Now Underway in Multiple Solid Tumor and Hematologic Malignancy Expansion Cohorts in Phase 1 Trial of Oral PRMT5 Inhibitor PRT543 - - Initial Clinical Data Readouts for Lead Oral PRMT5...
Prelude Therapeutics Announces Presentation at BofA Securities 2021 Virtual Health Care Conference
May 05, 2021 07:00 ET
|
Prelude Therapeutics, Inc.
WILMINGTON, Del., May 05, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (“Prelude”, “the Company”, “we”, “our”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that...